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Abstract
Background: Five pivotal clinical trials (Intensive Insulin Therapy; Recombinant Human Activated Protein C [rhAPC]; Low-
Tidal Volume; Low-Dose Steroid; Early Goal-Directed Therapy [EGDT]) demonstrated mortality reduction in patients with
severe sepsis and expert guidelines have recommended them to clinical practice. Yet, the adoption of these therapies
remains low among clinicians.
Objectives: We selected these five trials and asked: Question 1-What is the current probability that the new therapy is not
better than the standard of care in my patient with severe sepsis? Question 2-What is the current probability of reducing the
relative risk of death (RRR) of my patient with severe sepsis by meaningful clinical thresholds (RRR .15%; .20%; .25%)?
Methods: Bayesian methodologies were applied to this study. Odds ratio (OR) was considered for Question 1, and RRR was
used for Question 2. We constructed prior distributions (enthusiastic; mild, moderate, and severe skeptic) based on various
effective sample sizes of other relevant clinical trials (unfavorable evidence). Posterior distributions were calculated by
combining the prior distributions and the data from pivotal trials (favorable evidence).
Main Findings: Answer 1-The analysis based on mild skeptic prior shows beneficial results with the Intensive Insulin, rhAPC,
and Low-Tidal Volume trials, but not with the Low-Dose Steroid and EGDT trials. All trials’ results become unacceptable by
the analyses using moderate or severe skeptic priors. Answer 2-If we aim for a RRR.15%, the mild skeptic analysis shows
that the current probability of reducing death by this clinical threshold is 88% for the Intensive Insulin, 62–65% for the Low-
Tidal Volume, rhAPC, EGDT trials, and 17% for the Low-Dose Steroid trial. The moderate and severe skeptic analyses show no
clinically meaningful reduction in the risk of death for all trials. If we aim for a RRR .20% or .25%, all probabilities of
benefits become lower independent of the degree of skepticism.
Conclusions: Our clinical threshold analysis offers a new bedside tool to be directly applied to the care of patients with
severe sepsis. Our results demonstrate that the strength of evidence (statistical and clinical) is weak for all trials, particularly
for the Low-Dose Steroid and EGDT trials. It is essential to replicate the results of each of these five clinical trials in
confirmatory studies if we want to provide patient care based on scientifically sound evidence.
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Introduction
‘‘If we begin with certainties, we shall end in doubts; but if we begin
with doubts, and are patient with them, we shall end with certainties.’’
Sir Francis Bacon (1605)
More than 20 clinical trials involving over 10,000 patients have
been performed in patients with sepsis and severe sepsis in the last
15 years with little success in reducing mortality [1]. More
recently, five published clinical trials: Early Goal-Directed
Therapy [2], Recombinant Human Activated Protein C [3],
Low-Dose Steroid [4], Low-Tidal Volume-ARDS Network [5],
and Intensive Insulin Therapy [6] demonstrated positive outcome
results and brought the prospect of improving the survival of
patients with severe sepsis.
Ten multinational medical societies sponsored a joint statement,
‘Surviving Sepsis Campaign’, in which recommendations are
made to include the results of these trials in the standard of care for
patients with severe sepsis [7]. These recommendations have also
been evaluated by the Joint Commission on Accreditation of
Healthcare Organizations [8]. Despite these positive outcomes
and recommendations, scientists and clinicians have been either
slow or resistant to adopt the results of these trials at face value in
order to apply them to patient care [9–25]. Still, strong
endorsement by the medical societies is not coming without
criticisms and opposition by the medical community [8,26]. Why
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2291is this resistance to accept statistically significant results from large
clinical trials so accentuated in the sepsis field?
We propose that the genesis for most of these issues lies in the
confounding interpretation and poor translation of these results to
the bedside, and the lack of formal analysis combining previous
evidence and the current positive clinical trials. While controversy
is necessary for the progression of science [27], when it comes to
treating a patient with severe sepsis, a clinical decision is also
necessary for the betterment of this patient’s outcome.
In the following paragraphs, we argue that the best solution for
the understanding of pivotal clinical trials in severe sepsis can only
come from a friendly reunion of classic (frequentist) and Bayesian
statistical methodologies [28–31]. The application of this more
inclusive and robust interpretation of trial results will facilitate
their application directly to the bedside, and will hopefully further
improve the care of our patients with severe sepsis. Moreover, this
‘‘dualistic’’ approach will also empower us to better define the
need for confirmatory trials in order to optimize the current
standard of care.
Methods
A. Methods Background
The ‘‘early goal-directed therapy’’ (EGDT) trial [2] will be used
as a practical example to describe the rationale for our
methodology. This trial aimed to compare the use of early volume
replacement/vasopressor use in the treatment arm against
standard of care in the control arm for patients with severe sepsis.
The final results showed a 42% relative reduction in the risk of
death (16% absolute risk reduction) of in-hospital mortality with a
95% confidence interval (CI) (0.13–0.62), p=0.009. Common
clinical interpretations are: (a) there is only a 0.9% probability of a
false positive result (rejecting the null hypothesis when there is no
treatment difference); (b) there is a 95% probability of the true risk
ratio being somewhere between 0.13 and 0.62 (a reduction of 13–
62% in the relative risk of death). These interpretations are
incorrect due to the misunderstanding of the classic or frequentist
(frequency based view of probability) statistical reporting used in
this and most trials [32–35]. The correct interpretation of the
classic method for this trial is the following: There is a 0.9%
probability that results as good as or better than the ones found in
this trial (42% relative reduction in the risk of death), will be
observed among a large number of hypothetical repetitions of this
trial under the null hypothesis of no treatment effect. In addition,
the CIs generated from 95% of these hypothetical trials will cover
the true mortality reduction. This rather convoluted language is
the only possible interpretation which explicitly states that the
classic method cannot provide the probabilities that clinicians are
seeking for. In other words, clinicians are interpreting the
conventional p values and CIs as ‘current probabilities’, although
the classic method alone only provides us with probabilities over a
large number of hypothetical repetitions in the long term.
Here is where the Bayesian methodology comes in to
complement the classic interpretation of clinical trials. It allows
us to think the way most clinicians are already thinking [36]! That
is, what is the posterior or ‘current probability’ (not the probability
in the long term of hypothetical trial repetitions) of observing this
outcome in a given trial or population.
In order to use the Bayesian methodology, a prior probability is
required. The prior probability can be based on all available
evidence (i.e. biological rationale and its pre-clinical evaluation;
observational and experimental clinical data) gathered by studies
other than the new trial being currently analyzed. An analogy to
the diagnostic setting states that ‘‘it is not possible to find a
probability of having a disease based on tests results without
specifying the disease’s prevalence’’ [37]. The basic idea described
by Bayes demonstrates that the product between the prior
probability and the evidence provided by the new trial (also called
Bayes factor) will give us the posterior probability, which we call
the ‘‘current probability’’ in our paper. This simple and clever
algebraic calculation allows us to overcome the unsolvable ‘long
term hypothetical repetitions’ inherent issue of the classic method.
At the same time, it gives us what we are mostly looking for in our
daily medical practice, i.e. what is the current probability to
achieve the results of this pivotal trial in my patients? The potential
‘‘subjectivity’’ of these priors have made some statisticians and
clinicians concerned about the use of this method. However, the
complete exclusion of prior knowledge and evidence from the
design and interpretation of recently completed clinical trials has
been compared to a sentencing judge who overlooks the prior
convictions of a habitual criminal [38]. Needless to say, the
commonly used classic methodology in current clinical trials is far
from objective. For example, the models assumed, the parameters
and hypothesis chosen, and the experimental designs employed
[37] are typical features that incorporate much subjectivity into
the classic analysis. We agree with Berry [37] that ‘‘…silent
subjectivities such as these (seen with classic methods) are
dangerous in that they are difficult or impossible to make explicit.
By contrast, subjectivity in prior distributions (as seen with
Bayesian methods) is explicit and open to examination-and
critique-by all’’. Thus, how should we best determine the priors
for this study? This so-called subjectivity is easily resolved in the
severe sepsis world because we have many negative clinical trials
done before the current positive trials, which set the stage for the
perfect use of Bayesian methodology. We will provide the clinician
with a realistic spectrum of prior distributions, so he/she can find
the current probability of the new treatment being no better than
the control (standard of care), and the current probability of
reducing mortality by a clinically meaningful threshold. These two
probabilities will allow the clinician to make the best clinical
decision for the patient with severe sepsis without being entirely
dependent on sponsors, regulators, editors, and experts in the field.
B. Methods Description
1. What is the current probability that the new therapy is
not better than the standard of care in my patient with
severe sepsis?. The goal of the first part of our study is to assess
the current probability that the new therapy is no better than the
control, i.e. standard of care. We used the log-odds ratio (ln(OR))
of death for the new treatment group compared to the control
group. We considered the new therapy to be no better than the
control if the ln(OR) was found to be greater than 20.05 [38,39].
We then constructed various prior distributions of ln(OR)
assuming previous trials of different effective sample sizes (see
Appendix S1). The prior distributions may be based on the
following information: Early Goal-Directed Therapy [40–47],
rhAPC [48–53], Low-Dose Steroids [54–67], Low-Tidal Volume
[68–74], Intensive Insulin Therapy [75–85]. Of note, some trials
were performed before and others after the pivotal positive trial of
a given therapy. This inclusive approach of all evidence available
is an important strength of the Bayesian technique, which does not
require that the priors have a temporal order [32,37,86,87]. This
list of studies for each therapy allows the reader to get his/her own
effective sample size by summing up the prior unfavorable
evidence (total sample size of relevant negative clinical trials). If
believing there is no relevant previous negative data, one can
assume the effective sample size to be 1 [88]. This gives us the non-
informative prior, which is our ‘enthusiastic’ prior, since it is
Sepsis Trials
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skeptical about the effects of the new therapy based on previous
phase 2 and 3 trials, observational studies, or clinical experience,
the effective sample size of negative evidence for the (skeptical)
prior will be larger. Thus, the more skeptical one is based on the
prior information, the harder it is to conclude efficacy using the
same pivotal trial data. Based on the mortality rate and the
required sample size to evaluate new therapies for severe sepsis in
current times, the following effective sample sizes of negative
evidence were analyzed for each new therapy: Enthusiastic (n=1);
Mildly skeptic (n=200); Mild-moderately skeptic (n=500);
Moderately skeptic (n=1,000); Severely skeptic (n=2,000). We
consider the current probability of ln(OR) .20.05 being less than
0.05 as sufficient evidence to conclude that the new treatment is
better than the control. For example, if the clinician sums up
approximately 500 subjects from 3 previous negative trials on low-
tidal volume therapy [69–71] (i.e. mild to moderate skeptic about
this therapy), our analysis (table 1) will provide a 0.05 current
probability of low-tidal volume therapy being no better than
control. As the reader can appreciate in table 1, because of the
negative prior information that needs to be overcome, this current
probability (0.05) is different from the classic p value reported in
the original trial publication (p=0.007).
2. What is the current probability of decreasing the
relative risk of death of my patient with severe sepsis by a
meaningful clinical threshold? Based on the multitude of
clinical trials already published [1], the recent FDA approval of a
new therapy on sepsis [3], and a 28-day mortality ranging from
30–40%, no new therapy for severe sepsis will likely be accepted
by clinicians or regulators if the relative risk reduction (RRR) for
mortality is not greater than 15–25% (absolute risk reduction
(ARR) $5–10%). For example, a trial with a control arm mortality
of 30% and a experimental arm mortality of 25% would result in
an ARR=5% and a RRR=16%. Thus, we will present the
current probabilities for greater than 15%, 20%, and 25% RRR
for mortality in each trial (see Appendix S1). This second analysis
can be thought of as analogous to ‘clinical significance’. For
example, if the clinician sums up approximately 1000 subjects
from 2 previous negative trials on volume replacement/
vasopressor use [45,46] (i.e. moderate skeptic about this therapy)
and believes that a minimum of 15% RRR needs to be
demonstrated to add the EGDT to standard of care of patients
with severe sepsis, our analysis (table 2) will provide a 6% current
probability of reaching at least this RRR in mortality. This current
probability (6%) of reducing mortality by at least 15% is different
from the classic overall RRR reported in the original trial
publication (42%). This level of prediction can not be achieved
with classic methods alone.
The results of the five positive clinical trials [2–6] will be
discussed in the context of the two probability questions described
above. Because of the non-significant overall results of the low-
steroid trial for mortality [4], we will evaluate the prospectively
defined ‘‘non-responders’’ sub-population. Due to the low overall
control mortality (8%), and the inclusion of all comers (with and
without severe sepsis) to a surgical ICU in the intensive insulin trial
[6], we will evaluate the prospectively defined ‘‘.5 days in ICU’’
sub-population. This subgroup control had mortality rates (20%)
closer to those of the other trials. The rhAPC trial [3] will have two
analyses, since the drug was FDA approved based on the sicker
(APACHE II .25) sub-population. Even though the ARDSNet
Low-Tidal Volume trial [5] was not specifically designed for
patients with severe sepsis, we included it because approximately
60% of the trial population had sepsis or pneumonia, and the trial
results have been recommended for patients with severe sepsis by
practice guidelines [7].
Results
1. What is the current probability that the new therapy is
not better than the standard of care in my patient with
severe sepsis?
Table 1 shows the current probability of the new treatment
being no better than the control. If we are enthusiastic about the
five trials, all probabilities are small. If we are just mildly skeptic,
Table 1. Current probability of new treatment being no better than control based on mortality outcomes.
CLINICAL TRIALS (Favorable Evidence)
Early Goal-
Directed
Therapy
Activated
Protein C
Activated Protein C
(APACHE II .25)
Low-Dose
Steroids (Non-
Responders)
Low-Tidal
Volume
Intensive Insulin
Therapy (.5
days in ICU)
Published P values (Frequentist) 0.009 0.005 0.0002 0.02 0.007 0.005
Sample Size of Unfavorable Evidence (Bayesian Priors) CURRENT PROBABILITY OF NEW TREATMENT BEING NO BETTER THAN CONTROL
ENTHUSIASTIC (Sample Size=1) 0.01 0.009 0.0003 0.03 0.009 0.003
MILD SKEPTIC (Sample Size=200) 0.05 0.02 0.002 0.10 0.02 0.02
MILD-MODERATE SKEPTIC (Sample Size=500) 0.14 0.03 0.007 0.21 0.05 0.05
MODERATE SKEPTIC (Sample Size=1000) 0.25 0.05 0.03 0.33 0.10 0.12
SEVERE SKEPTIC (Sample Size=2000) 0.41 0.12 0.09 0.47 0.21 0.23
doi:10.1371/journal.pone.0002291.t001
Table 2. Probability of Relative Risk Reduction (RRR) of
Mortality by EGDT.
EARLY GOAL-DIRECTED THERAPY
SAMPLE SIZE OF
UNFAVORABLE EVIDENCE
CURRENT PROBABILITY OF RELATIVE
RISK REDUCTION
RRR.15% RRR.20% RRR.25%
ENTHUSIASTIC 94% 87% 78%
MILD SKEPTIC 62% 41% 22%
MILD-MODERATE SKEPTIC 27% 9% 2%
MODERATE SKEPTIC 6% 1% 0
SEVERE SKEPTIC 0.4% 0 0
doi:10.1371/journal.pone.0002291.t002
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trials become 0.05 or larger, which may not provide strong enough
evidence to change the standard of care. If we take into account
the preceding multitude of unfavorable trials and analyze these
results in the light of a mild-moderate skeptical view, the current
probabilities for these two trials rise to 0.14 and 0.21, respectively.
The results of rhAPC, Low-Tidal Volume, and Intensive Insulin
trials remain acceptable if we assume a mild skepticism-all with
current probabilities of less than 0.05. The mild-moderate skeptic
analysis makes both the Low-Tidal Volume and Intensive Insulin
results reach the 0.05 probability of the new treatment being no
better than the control, and the moderate skeptic analysis shows
the rhAPC trial with the same 0.05 probability as well. The rhAPC
APACHE II sub-analysis shows probabilities below 0.05 in all
prior levels except in the severe skeptic analysis. If the clinician is
severely skeptical, no trial results will lead to changes in the
standard of care.
2. What is the current probability of decreasing the
relative risk of death of my patient with severe sepsis by
a meaningful clinical threshold?
Table 2 illustrates the current probabilities of achieving at least a
specific clinically meaningful RRR based on the chosen cut-off and
prior distribution. For a clinician who is enthusiastic (i.e. choosing
the enthusiastic prior) about EGDT and believes that an RRR
should not be less than 20% to use this new therapy in patient care,
the chance of EGDT to decrease the relative risk of death more than
20% is 87%. If RRR.15% is the goal, this therapy will have a 94%
(enthusiastic) and 62% (mildly skeptic) current probabilities. This is a
tangible and easy result to translate and apply to bedside. For the
clinician who is mildly skeptical about this therapy, the chance of
EGDT to decrease the relative risk of death more than 20% in a
given patient will decrease to 41%, whichmay be too low for general
clinical application. If a moderately skeptical prior is applied to this
trial, the probability of having a RRR greater than 15% and 20%
drops substantially to 6% and 1%, respectively.
For the rhAPC overall results (table 3), in the best case scenario
(enthusiastic), the current probability of reaching a 20% RRR in
mortality is 43%. If the clinician is comfortable with a 15% RRR,
then the probability of reaching this cut-off with rhAPC goes up to
75% for the enthusiastic, and to 65% for the mildly skeptical, but
remains low at 30% for the moderately skeptical. On the other
side, if we analyze this trial based on APACHE II .25 subgroup
and enthusiastic prior, then there is 97%, 90%, and 72%
probability of respectively reaching RRR of 15%, 20%, and
25% with rhAPC. These are more optimistic results than the
overall trial analysis, but if the clinician remains a mild-moderate
skeptic, the probability of achieving any of those same RRR
thresholds becomes smaller; 63%, 30%, and 7%, respectively. The
moderate and severe skeptic analyses show most probabilities of
reaching any meaningful RRR in the single digits.
The Low-Dose Steroid trial analysis demonstrates well the
importance of this type of clinical threshold analysis. In the best
case-scenario for the least meaningful RRR (15%), the enthusiastic
approach shows a current probability of 58% (table 4). Even for
the mildly skeptic, steroids have an unacceptably low current
probability (20% or less) of reaching any meaningful RRR in
mortality. We also performed an additional analysis about the
probability of steroids reaching a RRR.10%, but except for the
enthusiastic prior (76%), all other probabilities remain similarly
poor (41% or less).
The Low-Tidal Volume trial (table 5) shows a current
probability of 83% (enthusiastic) or 65% (mild skeptic) for the
physician who is looking for a RRR.15%. However, for the
mildly skeptic requiring a RRR.20% the probability drops to
37%, and for the mild-moderate skeptic requiring any RRR, the
probabilities of benefit from this therapy remain all below 40%.
The Intensive Insulin trial (table 6) shows consistent probabil-
ities of reducing the risk of death (69–98%) for all RRR levels in
both enthusiastic and mild skeptic analyses. The probability
remains above 60% even in the mild-moderate skeptic analysis if
the aim is a RRR.15%. However, for the moderate or severe
skeptic approach, all results are below 42%.
Discussion
The first analysis indicates that there is sufficient evidence to
support the efficacy in all five trials only if we are enthusiastic with
respect to the prior distribution of each of these therapies. If we
analyze them with the mild skepticism, only the Intensive Insulin,
rhAPC, and Low-Tidal Volume trials show beneficial results.
Table 3. Probability of Relative Risk Reduction (RRR) of
Mortality by recombinant human APC.
ACTIVATED PROTEIN C
SAMPLE SIZE OF
UNFAVORABLE EVIDENCE
CURRENT PROBABILITY OF RELATIVE
RISK REDUCTION
RRR .15% RRR .20% RRR .25%
ENTHUSIASTIC 75% 43% 14%
MILD SKEPTIC 65% 31% 7%
MILD-MODERATE SKEPTIC 50% 17% 3%
MODERATE SKEPTIC 30% 6% 0.4%
SEVERE SKEPTIC 9% 0.5% 0
ACTIVATED PROTEIN C (APACHE II .25)
SAMPLE SIZE OF
UNFAVORABLE EVIDENCE
CURRENT PROBABILITY OF RELATIVE
RISK REDUCTION
RRR .15% RRR .20% RRR .25%
ENTHUSIASTIC 97% 90% 72%
MILD SKEPTIC 88% 66% 35%
MILD-MODERATE SKEPTIC 63% 30% 7%
MODERATE SKEPTIC 27% 5% 0.2%
SEVERE SKEPTIC 3% 0.1% 0
doi:10.1371/journal.pone.0002291.t003
Table 4. Probability of Relative Risk Reduction (RRR) of
Mortality by Low-Dose Steroid.
LOW-DOSE STEROID
SAMPLE SIZE OF
UNFAVORABLE EVIDENCE
CURRENT PROBABILITY OF RELATIVE
RISK REDUCTION
RRR .15% RRR .20% RRR .25%
ENTHUSIASTIC 58% 37% 19%
MILD SKEPTIC 17% 4% 0.5%
MILD-MODERATE SKEPTIC 3% 0.1% 0
MODERATE SKEPTIC 0.1% 0 0
SEVERE SKEPTIC 00 0
doi:10.1371/journal.pone.0002291.t004
Sepsis Trials
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beneficial in the moderate skeptic analysis, the original results have
not been validated in a prospective phase III trial yet. Based on
our current results indicating high probability of new treatment
being no better than controls in all skeptic analyses for the EGDP
and Low-Dose Steroid trials, as well as on the numerous
unfavorable trials evaluating different regimens of volume
replacement/vasopressors or steroids in severe sepsis, we demon-
strate that the beneficial results from these two trials are the ones
with the weakest strength of evidence. All five trials become
unacceptable if we are moderately or severely skeptical, because
the current probability of the new therapy being no better than the
control is too high for general clinical application. The fact that
most overall beneficial results are not even that impressive with the
mild-moderately skeptic analysis is concerning.
The second analysis based on a specific clinical cut-off of the
RRR brings important light to the interpretation of these trials.
Assuming an enthusiastic prior, the Intensive Insulin, the rhAPC
APACHE II .25, and the EGDP trials demonstrate the highest
probability (87–96%) of reaching an RRR of at least 20% for
mortality. However, the absence of a majority of patients with
severe sepsis in the Intensive Insulin trial, the absence of
prospective validation of the rhAPC APACHE II .25 subgroup
population, and the weak strength of evidence from our first
analysis for the EGDP trial, all suggest that more skepticism should
be taken before assuming these probabilities of RRR.20%. In
this case, the moderate skeptic analysis for these 3 trials shows all
current probabilities of 23% or less of reducing death risk by more
than 20%. On the other hand, if we are mildly skeptical and aim a
RRR.15%, the probability of reducing the risk of death is 88%
for the Intensive Insulin trial, 62–65% for the rhAPC, Low-Tidal
Volume, and EGDT trials, and just 17% for the Low-Dose Steroid
trial. Unless we are less ambitious with respect to the RRR, i.e.
15%, and accept an enthusiastic to mildly skeptic prior, none of
these trials have shown strong enough evidence for diminishing the
risk of death in patients with severe sepsis. Of note, the consistently
very low current probabilities (poor strength of evidence) of
observing mortality reduction with Low-Dose Steroids in both of
our analyses (questions 1 and 2) was just confirmed by a recently
published phase III trial [66]. Interestingly, our statistical analysis
predicting the poor results of Low-Dose Steroids was completed
and submitted long before the report of this new phase III trial.
We would like to recognize some limitations of our study. The
statistical approach we used for this study may appear to produce
more conservative results than conventional methods, but this is,
in fact, the main strength of our data. The Bayes’ theorem is
uncontroversial if derived from known data [88]. We strongly
believe that the prior negative evidence is so abundant that we
have the ethical obligation to consider and use this methodology in
the analysis of any new therapy for severe sepsis. The different
sample sizes of each trial may have influenced the current
probabilities of our first analysis, but the consistent results found in
both first and second analyses make the sample size influence less
likely. Also, because some of the therapeutic interventions were
not identical within a specific class, and other studies were different
with respect to their trial design, we advise the reader to carefully
evaluate the most appropriate priors to avoid overt pessimistic or
optimistic current probabilities.
In conclusion, our study provides four clinical and research
lessons with profound implications to the care of our patients with
severe sepsis:
Lesson 1–Need for confirmatory trials
Our results unambiguously demonstrate that it is important to
replicate the results of each of these trials in well designed
confirmatory studies if we want to provide patient care based on
scientifically sound evidence. Further, the many study design issues
raised, e.g. standard of care of control groups (EGDT and Low-
Tidal Volume trials [10–12,17,21–24]; the rhAPC APACHE II
.25 subgroup analysis without prospective validation [3] and the
poor results of this subgroup in the ADDRESS trial [49,89]; the
controversial definitions of adrenal insufficiency [20,90,91], and
the just reported Low-Dose Steroid phase III trial with negative
results [66]; and the failure of the Intensive Insulin Therapy to
improve survival in the medical ICU population [75] all
corroborate our conclusion for lesson 1.
Lesson 2–Standard of care for patients with severe sepsis
The strength of evidence (statistical and clinical) is overall weak
for the five trials. These results make any legitimate changes in the
standard of care a very difficult task to accomplish. While we
endorse the genuine need for more evidence, we are aware of the
urgent need to improve the survival outcome of our patients with
severe sepsis. How to reconcile this apparent conundrum? Sir
Austin Hill already had the answer in his seminal paper from
1965: ‘‘All scientific work is incomplete–whether it be observa-
tional or experimental. All scientific work is liable to be upset or
modified by advancing knowledge. That does not confer on us a
freedom to ignore the knowledge that we already have, or to
postpone the action that it appears to demand at a given time’’
[92]. Before we have the results of confirmatory trials, we urge
clinicians to use our clinical threshold analysis of RRR for
Table 5. Probability of Relative Risk Reduction (RRR) of
Mortality by Low-Tidal Volume.
LOW-TIDAL VOLUME
SAMPLE SIZE OF
UNFAVORABLE EVIDENCE
CURRENT PROBABILITY OF RELATIVE
RISK REDUCTION
RRR .15% RRR .20% RRR .25%
ENTHUSIASTIC 83% 62% 34%
MILD SKEPTIC 65% 37% 13%
MILD-MODERATE SKEPTIC 41% 14% 2%
MODERATE SKEPTIC 16% 2% 0.1%
SEVERE SKEPTIC 2% 0 0
doi:10.1371/journal.pone.0002291.t005
Table 6. Probability of Relative Risk Reduction (RRR) of
Mortality by Intensive Insulin Therapy.
INTENSIVE INSULIN THERAPY
SAMPLE SIZE OF
UNFAVORABLE EVIDENCE
CURRENT PROBABILITY OF RELATIVE
RISK REDUCTION
RRR .15% RRR .20% RRR .25%
ENTHUSIASTIC 98% 96% 93%
MILD SKEPTIC 88% 80% 69%
MILD-MODERATE SKEPTIC 68% 52% 35%
MODERATE SKEPTIC 42% 23% 9%
SEVERE SKEPTIC 16% 4% 0.6%
doi:10.1371/journal.pone.0002291.t006
Sepsis Trials
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action to take for their patients with severe sepsis.
Lesson 3–No need for changes in the measurement of
ICU quality of care
The most important premise to change the measurement of
quality of care must be based on strong and established scientific
evidence, but this is lacking at this time. When we completed our
study it became obvious that, with such low strength of evidence
and critical need for confirmatory trials, none of these studies’
results should be applied as rigid tools to measure quality of care in
patients with severe sepsis in the ICU.
Lesson 4–Need for both classic and Bayesian
interpretation of clinical trials
As we demonstrate in this paper, the dual use of these methods
is powerful and synergistic to accomplish an ample interpretation
of these pivotal trials. We strongly suggest that trialists, sponsors,
regulators, and journal editors become more proactive with
respect to the use of this dual statistical approach. Patients will be
the ultimate beneficiaries from this more encompassing strategy.
We anticipate that our comprehensive analysis and interpreta-
tion of these trials will bestow realistic and practical tools to
clinicians to decide on their own and without undue influence how
to best apply the results of these trials to their patients with severe
sepsis.
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